It wasn’t a subject Deepak Ghaisas understood at all. But he was trying, even before he fully exited i-flex, a financial product company that he had incubated at Citi Group, which was acquired by Oracle in 2005. When Ghaisas did exit, in 2008, he was convinced he wanted to do something “different at age 50”. A year later, that something turned out to be stem cells. As someone who would attend seminars and text his biologist wife to understand the difference between ‘in vitro’ (in a lab) ‘in vivo’ (in an organism), Ghaisas’ foray into stem cells, a class of cells that can repair organs and promise to cure some diseases, was rather unusual.

In late 2010, Stemade Biotech, Ghaisas’ new venture, announced that its dental stem cells banks were operational across a few cities in India. The nature of his bank took everyone by surprise. Around that time, nearly a dozen stem cell banks were being set up in India but all stored umbilical cord blood, a source of these cells. Ghaisas had gone to France, invested in an R&D outfit, Institut Clinident Biopharma, and brought the technology to Stemade in India. It would harvest dental pulp, from which stem cells could be extracted. Plans were afoot, in plenty: To start R&D, preclinical studies with hospitals, and commercialise a few therapies.

Now, six years later, Stemade claims to have 5,000 units stored but almost everything else is elusive. The company grossed Rs 3.4 crore in revenue for the year ending March 31, 2015, and booked a loss of Rs 3 crore. Most of the other stem cell banks, even though an established business in other parts of the world, aren’t in good shape either. LifeCell International, India’s largest cord blood bank, has seen a steady decline in profitability in the last five years, it recorded a loss of Rs 55 crore on revenues of Rs 141 crore in FY15.

Even if in fits and starts, these banks have been adding to their collection of cord blood units and dental pulp but they are at best non-performing assets. While Ghaisas would like to assign a good part of the mounting losses to the government’s withdrawal of service tax exemption to such banks since February 2013; the reality is a little more complex.

Is being ‘private’ the roadblock?

Storing umbilical cord blood in private banks is like ‘biological insurance’ against illnesses. That’s been a popular catchline for these banks. Parents who bank their children’s cord blood can use it for the family’s personal use. But the usage of these cells is so low that the need for this service is under question.

To set this in context, LifeCell, which its vice chairman Mayur Abhaya claims, has 200,000 units stored, is on its way to becoming one of the largest banks in the world.

AUTHOR

Seema Singh

Seema has over two decades of experience in journalism. Before starting The Ken, Seema wrote “Myth Breaker: Kiran Mazumdar-Shaw and the Story of Indian Biotech”, published by HarperCollins in May 2016. Prior to that, she was a senior editor and bureau chief for Bangalore with Forbes India, and before that she wrote for Mint. Seema has written for numerous international publications like IEEE-Spectrum, New Scientist, Cell and Newsweek. Seema is a Knight Science Journalism Fellow from the Massachusetts Institute of Technology and a MacArthur Foundation Research Grantee.

View Full Profile

Subscribe to read this story

The Ken is the only business subscription you need. Questions?

 

Premium

  • 5 original and reported longform business stories every week
  • Access to ONLY India edition
  • Close to 250 exclusive stories every year
  • Full access to over 5 years of paywalled stories
  • Pick up to 5 premium subscriber newsletters
  • 4 original and reported longform business stories each week
  • Access to ONLY Southeast Asia edition
  • Close to 200 exclusive stories every year
  • Full access to all paywalled stories since March 2020
  • Pick up to 5 premium subscriber newsletters

Rs. 2,750 /year

$ 120 /year

India Edition
Subscribe Subscribe
Most Asked For

Borderless

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 5 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories

Rs. 4,200 /year

Subscribe
 

Echelon

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 5 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories
  • Bonus annual gift subscription
  • Priority access to all new products and features

Rs. 8,474 /year

Subscribe
Or

Questions?

What kind of subscription plans do you offer?

We have three types of subscriptions
- Premium which gives you access to either the India or the Southeast Asia edition.
- Borderless which gives you complete access to The Ken across both editions
- Echelon which gives you complete access to The Ken across both editions along with a bonus gift subscription

What do I get if I subscribe?

The Premium edition gives you access to stories in that edition along with any five subscriber-only newsletters of your choice.

The Borderless and Echelon subscription gives you complete access to The Ken across editions and unlimited access to as many newsletters as you like.

What topics do you usually write about?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics. We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

Our specialised subscriber-only newsletters are written by our expert, award-winning journalists and cover a range of topics across finance, retail, clean energy, cryptocurrency, ed-tech and many more.

How many newsletters do you have?

We are constantly adding specialised subscriber-only newsletters all the time. All of these are written by our team of award-winning journalists on a specialised topic.

You can see the list of newsletters that we publish over here.

Does a Premium subscription to your Indian edition get me access to the Southeast Asia edition? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

We recommend the Borderless or the Echelon Plan which will give you access to stories across both editions.

Do you have a mobile app?

Yes! We have a top-rated mobile app on both iOS and Android which allows you to read on-the-go and has some amazing features like the ability to bookmark stories, save on your device, dark mode, and much more. It’s really the best way to read The Ken.

Is there a free trial?

You can sign up for a free account to experience The Ken and understand our products better. We’ll send you some free stories and newsletters occasionally, and you can access our archive of previously published free stories. You can stay on the free account as long as you’d like.

The vast majority of our stories, articles and newsletters can be accessed only by a paid subscription.

Do you offer any discounts?

Sorry, no. Our journalism is funded completely by our subscribers. We believe that quality journalism comes at a price, and readers trust and pay us so that we can remain independent.

Do you offer refunds?

No. We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Just write to us at [email protected] with details. We’ll help you out.

I have a few more questions. How can I reach out to you?

Sure. Just email us at [email protected] or follow us on Twitter.